Breakthrough in Retinal Diseases: AI Detection and Treatment

CME

This activity is jointly provided by Partners for Advancing Clinical Education (PACE), and DKBmed. This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Enduring Activity

Estimated time to complete this activity: 60 minutes 

There is no fee for this educational activity.

For CME questions, please visit https://partnersed.com/. 

Target Audience

The target audience includes ophthalmologists and retina specialists. 

Learner Outcomes

After completing this activity, the participant should be better able to: 

  • Discuss consequences of delayed treatment initiation for patients with neovascular age-related macular degeneration (nAMD).   
  • Discuss consequences of delayed treatment initiation for patients with diabetic macular edema (DME).   
  • Describe efficacy and safety of newer anti-VEGF treatments for nAMD.   
  • Evaluate the benefits of newly available treatment anti-VEGF options for diabetic retinopathy (DR) and DME. 

Faculty

Rishi P. Singh, MD, FASRS 
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine  Cleveland Clinic Martin Health  

David Eichenbaum, MD, FASRS 
Director of Research, Retina Vitreous Associates of Florida
Collaborative Associate Professor, Morsani College of Medicine, University of South Florida 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), DKBmed, and the Institute for Johns Hopkins Nursing. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

PACE designates this material enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.  

Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.  

Faculty / Presenter Reported Financial Relationship

Rishi P. Singh, MD, FASRS 
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Martin Health 

  • Consultant, Advisor, Speaker: Alcon, Allergan/Abbvie, Apellis, Eyepoint, Iveric, Genentech/Roche, Regeneron Pharmaceuticals, Inc., Zeiss 

David Eichenbaum, MD, FASRS 
Director of Research, Retina Vitreous Associates of Florida
Collaborative Associate Professor, Morsani College of Medicine, University of South Florida 

  • Researcher: 4DMT, Aerie, Alexion, Allegenesis, Astellas, Aviceda, Bayer, EyePoint, Genimi, Genentech, Gyroscope, Ionis, Kodiak, Mylan, NGM, Novartis, Ocular Therapeutix, OcuTerra, Opthea, ONL, RegenxBio, Roche, Unit  
  • Consultant, Advisor, Speaker: Alimera, Allergan, Astellas, Bausch & Lomb, Bayer, Coherus/Sandoz, CorEvitas/Vestrum, Crinetics, EyePoint, Genentech, Kodiak, Novartis, Ocular Therapeutix, Ocuphire, Opthea, Outlook, Recens Medical, RegenxBio, ReVive, Roche, Samsara   
  • Equity Ownership: Boston Image Reading Center, US Retina 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.  

Request for Credit/Fees

There are no fees for participating and receiving CME contact hours credit for this activity. During the period of September 1, 2024 through September 1, 2025, participants must read the learning objectives and faculty disclosures and study the educational activity. 

Hardware/Software Requirements

Include minimum hardware, software, internet connectivity and connection speed requirements for accessing the internet-based activity.